Physician profile
Lin-Wang Dong
NPI 1114064490
$3,164.43
in general payments reported to CMS, 2019-2025
19 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $258 · 2021: $380 · 2022: $376 · 2023: $61.73 · 2024: $1,497 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,200 · Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,200.00 |
| Food and Beverage | $648.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $1,200.00 | 2024 | Juxtapid |
| Actelion Pharmaceuticals US, INC. | $499.10 | 2019-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $420.02 | 2020-2025 | |
| Abbott Laboratories | $374.32 | 2020-2024 | Cardiomems |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| United Therapeutics Corporation | $148.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $101.09 | 2024 | Winrevair |
| Philips North America LLC | $65.90 | 2023-2025 | Extended Holter, (Ck4) Mcot |
| Janssen Pharmaceuticals, INC | $41.82 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.94 | 2022 | |
| Gilead Sciences, INC. | $24.04 | 2019 | |
| Boston Scientific Corporation | $22.36 | 2021 | |
| Amgen INC. | $18.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.21 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.56 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin-Wang Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.